<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951558</url>
  </required_header>
  <id_info>
    <org_study_id>HIM-2017-046</org_study_id>
    <nct_id>NCT03951558</nct_id>
  </id_info>
  <brief_title>Comparison of the Impact of Diet vs Thiazide in BMD in Children With Idiopathic Hypercalciuria</brief_title>
  <acronym>HIC</acronym>
  <official_title>Comparison of the Impact of Nutritional Treatment vs Hydrochlorothiazide on Bone Mineral Density and Body Composition in Children With Idiopathic Hypercalciuria of the Hospital Infantil de Méxio Federico Gómez</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Infantil de Mexico Federico Gomez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Infantil de Mexico Federico Gomez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's objective is to compare and evaluate the impact of nutritional treatment
      vs. pharmacological treatment (hydrochlorothiazide) in bone mineral density in children with
      idiopathic hypercalciuria.

      A randomized, open-label, one-year follow-up study will be conducted in children aged 5 to 21
      years with a confirmed diagnosis of idiopathic hypercalciuria or lithiasis, excluding those
      patients with secondary hypercalciuria (primary hyperoxaluria, treatment with vitamin D,
      Bartter syndrome, primary hyperparathyroidism), previous kidney transplantation. The impact
      of diet (hyposodic, calcium intake according to DIR for age, normal protein intake and high
      water intake) will be evaluated vs. the pharmacological treatment (hydrochlorothiazide) on
      bone mineral density.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label clinical trial will be conducted with a one-year follow-up. For
      which basal measurement of calciuria, citraturia, serum creatinine, serum and urinary
      electrolytes, parathyroid hormone, vitamin D levels and renal ultrasound, as well as dietary
      intake (protein, energy, salt and water). The dietary intake per day of food and
      pharmacological treatment will be evaluated quarterly, body composition (anthropometry) and
      serum and urinary electrolyte levels will be measured; Bone constitution (DXA, quantitative
      bone ultrasound), IL-1 (as inflammatory markers) and vitamin D will be evaluated every six
      months.

      Participants will be blinded to the pharmacological treatment they will receive. The
      randomization of the participants will be done through the page www.randomization.com. The
      randomization was performed by blocks, where blocks of 6 members each were made i. Group 1:
      only recommendations of water intake and reduction of salt intake and hydrochlorothiazide
      will be given (the dose will be assigned according to weight and sex by a pediatric
      nephrologist, dose of 0.5-1.5mg / kg / day, starting with the dose 1 mg / kg).
      Hydrochlorothiazide will be provided to the patient.

      ii. Group 2: placebo capsules and a strict diet plan will be given. The placebo will look
      similar to that of hydrochlorothiazide and will be prepared in the Nephrology Research
      Laboratory by Biol. Ana María Hernández Sánchez and Quim Lourdes Ortiz. The feeding plan will
      be appropriate for the patient, it will consist of:

        1. 40 ml / Kg / day of water

        2. Protein according to age and sex

        3. Recommendations for low sodium intake

        4. Calcium according to age and sex (minimum 800mg)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The capsules are the same color in the placebo group and the intervention group. The content of the capsules is similar in both groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density</measure>
    <time_frame>one year</time_frame>
    <description>bone mineral density will be evaluated by means of score z evaluated by dexa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ca/Cr index</measure>
    <time_frame>one year</time_frame>
    <description>urinary calcium excretion will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hypercalciuria; Idiopathic</condition>
  <condition>Nephrolithiasis</condition>
  <arm_group>
    <arm_group_label>Diet for calciuria prevention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo capsules and a strict eating plan will be given. The placebo will look similar to that of hydrochlorothiazide and will be prepared in the Nephrology Research Laboratory by Biol. Ana María Hernández Sánchez and Quim Lourdes Ortiz.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrochlorothiazide for calciuria prevention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>recommendations for water intake and decrease in salt intake will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet for calciuria prevention</intervention_name>
    <description>Dietary recommendations for water, salt, calcium and proteins according to age and DIR</description>
    <arm_group_label>Diet for calciuria prevention</arm_group_label>
    <other_name>Diet for hypercalciuria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydroclorothiazide recommendations for hypercalciuria</description>
    <arm_group_label>hydrochlorothiazide for calciuria prevention</arm_group_label>
    <other_name>Hydroclorothiazide in hypercalciuria</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of idiopathic hypercalciuria

          -  Man or women

          -  5 to 21 years

        Exclusion Criteria:

          -  Clinical diagnosis of secondary hypercalciuria (primary hyperoxaluria, treatment with
             vitamin D, Bartter syndrome, primary hyperparathyroidism)

          -  Previous kidney transplant

          -  Clinical diagnosis of kidney disease.

          -  Vitamin D intake (more than 800 mg/day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Ortiz, Master</last_name>
    <role>Study Chair</role>
    <affiliation>UNAM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ma Elena Ortiz Cornejo, Master</last_name>
    <phone>(52) 01 55 5228 9917</phone>
    <phone_ext>4410</phone_ext>
    <email>meocnutricion@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mara Medeiros Domingo, PhD</last_name>
    <phone>(52) 01 55 5228 9917</phone>
    <phone_ext>4410</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Mexico, Federico Gómez</name>
      <address>
        <city>México</city>
        <state>México City</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ma Elena Ortiz Cornejo, Master</last_name>
      <phone>(52) 01 55 5228 9917</phone>
      <phone_ext>4410</phone_ext>
      <email>meocnutricion@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mara Medeiros Domingo, PhD</last_name>
      <phone>(52) 01 55 5228 9917</phone>
      <phone_ext>4410</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Infantil de Mexico Federico Gomez</investigator_affiliation>
    <investigator_full_name>Mara Medeiros</investigator_full_name>
    <investigator_title>Ph D Mara Medeiros Domingo</investigator_title>
  </responsible_party>
  <keyword>diet</keyword>
  <keyword>drinking water</keyword>
  <keyword>salt</keyword>
  <keyword>dietaryprotein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>a report of results will be made by means of a research article and information will be provided that researchers interested in the obtained data request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>will be available at within one year</ipd_time_frame>
    <ipd_access_criteria>Requests for additional information will be reviewed by Nutriologa Ma Elena Ortiz and PhD. Mara Medeiros Domingo</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

